Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee J Chng, MD MRCP, FRCPATH, PhD, Kihyun Kim, MD PhD, Jeffrey Huang, Chor Sang Chim, MBChB, Hiroshi Kosugi, MD PhD, Naoki Takezako, MD PhD, Junichi Sakamoto, MD PhD, Sathish Kumar Gopalakrishnan, Yuan Wei, Ling Ying Zhuo, Je-Jung Lee, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Chang-Ki Min, Jae-Hoon Lee, Brian G M Durie

Blood (2016) 128 (22): 2130.

https://doi.org/10.1182/blood.V128.22.2130.2130

Published: 2016

Journal Articles

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Melissa G. Ooi, MDMRCP FRCPath PhD, Wee J Chng, MD MRCP, FRCPATH, PhD, Chin-Hin Ng, MD MRCP, FRCPATH, Yi Ching Yuen, MClinPharm, BCOP, BCPS, CGP, Allen Eng Juh Yeoh, MD, Chiew Kean Hui, Elaine Seah, BSc

Blood (2016) 128 (22): 5162.

https://doi.org/10.1182/blood.V128.22.5162.5162

Published: 2016

Journal Articles

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

Wee J. Chng, MD, Marta Chesi, PhD, Tammy Price-Troska, Greg Ahmann, Kim Henderson, Philip Greipp, MD, Robert Kyle, MD, S. Vincent Rajkumar, MD, Morie Gertz, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD

Blood (2007) 110 (11): 241.

https://doi.org/10.1182/blood.V110.11.241.241

Published: 2007

Journal Articles

Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor.

Wee J. Chng, MD, Jonathan J. Keats, PhD, Esteben Braggio, PhD, Angela Baker, PhD, P. Leif Bergsagel, MD, John Carpten, PhD, Rafael Fonseca, MD

Blood (2007) 110 (11): 1476.

https://doi.org/10.1182/blood.V110.11.1476.1476

Published: 2007

Journal Articles

Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).

Wee J. Chng, MD, Tae-Hoon Chung, PhD, Jonathan J. Keats, PhD, Angela Baker, PhD, P. Leif Bergsagel, MD, John Carpten, PhD, Rafael Fonseca, MD

Blood (2007) 110 (11): 2471.

https://doi.org/10.1182/blood.V110.11.2471.2471

Published: 2007

Journal Articles

Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.

Wee J. Chng, MD, Rafael Fonseca, MD, Peter Leif Bergsagel, MD, Julia A. Vrana, Paul J. Kurtin, MD, Ellen Remstein, MD, Ahmet Dogan, MD

Blood (2007) 110 (11): 560.

https://doi.org/10.1182/blood.V110.11.560.560

Published: 2007

NARROW

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor.

Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).

Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.

Email alerts

ASH Publications

American Society of Hematology

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Paediatric-Inspired Acute Lymphoblastic Leukemia Protocols, Are They Too Toxic for Young Adults?

Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).

Multiple Myeloma (MM) Is Characterized by Genomic Instability Regardless of Ploidy Categories and Degree of Karyotypic Complexity Is an Important Prognostic Factor.

Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).

Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only